mecamylamine has been researched along with Amblyopia, Developmental in 1 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morishita, H | 1 |
| Miwa, JM | 1 |
| Heintz, N | 1 |
| Hensch, TK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Recovery From Amblyopia With Cholinesterase Inhibitors[NCT01584076] | Phase 1 | 18 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for mecamylamine and Amblyopia, Developmental
| Article | Year |
|---|---|
Lynx1, a cholinergic brake, limits plasticity in adult visual cortex.
Topics: Adaptor Proteins, Signal Transducing; Aging; Amblyopia; Animals; Cholinesterase Inhibitors; Dominanc | 2010 |